Algonist Biotechnologies

Algonist Biotechnologies is a preclinical-stage biotechnology company focused on developing novel, non-opioid therapeutics for chronic and neuropathic pain. The company's primary approach involves the modulation of N-type voltage-gated calcium channels (CaV2.2) through the disruption of their interaction with the regulatory protein CRMP2 (Collapsin Response Mediator Protein 2). By utilizing small molecule inhibitors to target this specific protein-protein interaction, Algonist aims to provide effective pain relief while avoiding the addiction risks and side effects associated with opioid-based treatments. The company's technology is based on extensive research conducted at the University of Arizona and NYU Langone Health. Algonist has received significant funding from the National Institutes of Health to advance its lead candidates toward clinical trials.